Fosfomycin

What is Fosfomycin?

Fosfomycin is a unique broad-spectrum antibiotic belonging to the phosphonic acid derivative class. It is distinguished by its novel mechanism of action, which targets bacterial cell wall synthesis at an early stage. Classified under the ATC code J01 (Antibacterial for systemic use), Fosfomycin is primarily recognized for its efficacy in treating urinary tract infections (UTIs), particularly uncomplicated acute cystitis in women. Its distinct chemical structure and mode of action make it a valuable option, especially in an era of increasing antimicrobial resistance.

Available in both oral (as Fosfomycin trometamol) and intravenous (as Fosfomycin disodium) formulations, this antibiotic demonstrates bactericidal activity against a wide range of common Gram-positive and Gram-negative uropathogens, including Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus saprophyticus. The oral formulation is often prescribed as a single-dose treatment for uncomplicated UTIs, offering convenience and promoting patient adherence. The intravenous form is reserved for more severe or complicated infections, sometimes in combination with other antibiotics to enhance its spectrum or overcome resistance mechanisms.

Mechanism of Action

The bactericidal action of Fosfomycin stems from its unique ability to disrupt an essential early step in bacterial cell wall synthesis. Unlike beta-lactam antibiotics or glycopeptides, which target later stages, Fosfomycin acts much earlier in the peptidoglycan synthesis pathway. This distinct mechanism helps to minimize cross-resistance with other classes of antibiotics, making it an important agent against multi-drug resistant strains.

• Fosfomycin irreversibly inhibits UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), an enzyme crucial for the synthesis of N-acetylmuramic acid.
• MurA catalyzes the transfer of enolpyruvate from phosphoenolpyruvate (PEP) to UDP-N-acetylglucosamine, forming UDP-N-acetylglucosamine-3-enolpyruvyl ether.
• By mimicking PEP, Fosfomycin covalently binds to a cysteine residue in the active site of MurA, thereby inactivating the enzyme.
• This inhibition prevents the formation of N-acetylmuramic acid, a vital precursor for peptidoglycan, leading to defective bacterial cell walls.
• The disruption of cell wall integrity ultimately results in bacterial lysis and death, demonstrating its potent bactericidal effect.

Medical Uses

Primary Uses:

• Uncomplicated Urinary Tract Infections (UTIs) in adult women, specifically acute bacterial cystitis, caused by susceptible strains of E. coli and Enterococcus faecalis.

Secondary Uses (often off-label or for IV formulation):

• Complicated Urinary Tract Infections (cUTIs), including pyelonephritis, often in combination with other antibiotics.
• Prophylaxis for transrectal prostate biopsy to prevent infectious complications.
• Treatment of multi-drug resistant (MDR) bacterial infections, including those caused by ESBL-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), and vancomycin-resistant Enterococci (VRE), particularly when administered intravenously and often as part of a combination therapy.
• Bone and joint infections, and ventilator-associated pneumonia, especially in cases involving resistant pathogens.

Dosage

Side Effects

While generally well-tolerated, Fosfomycin can cause side effects. Most are mild and transient, but some can be serious.

Common Side Effects:

• Nausea
• Diarrhea
• Headache
• Dizziness
• Abdominal pain
• Dyspepsia
• Vaginitis
• Rhinitis
• Fatigue

Rare but Serious Side Effects:

• Angioedema (swelling beneath the skin)
• Anaphylaxis (severe allergic reaction)
• Clostridioides difficile-associated diarrhea (CDAD), ranging from mild diarrhea to fatal colitis
• Severe skin reactions (e.g., Stevens-Johnson syndrome)
• Aplastic anemia (very rare with oral form)
• Hepatotoxicity (liver damage, rare)

Warnings

Fosfomycin is contraindicated in individuals with known hypersensitivity to the drug or any of its components. The oral formulation is also contraindicated in patients with severe renal impairment (creatinine clearance <10 mL/min) due to reduced elimination and potential for accumulation. Caution should be exercised in patients with a history of Clostridioides difficile-associated diarrhea, as antibiotic use, including Fosfomycin, can alter normal gut flora and lead to CDAD. Pregnant and breastfeeding women should use Fosfomycin only if clearly needed and under strict medical supervision, as its safety in these populations has not been definitively established.

This article provides general medical information and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment of any medical condition or before making any decisions related to your health or treatment. The information presented here is for educational purposes only and should not be used as a substitute for professional medical guidance.